Study designs of evaluations included in the review
Randomised controlled trials (RCTs) comparing single-agent with combination chemotherapy were included.
Specific interventions included in the review
Single agent and combination chemotherapy in NSCLC. Single agents included are: cyclophosphamide, vindesine, etoposide, cisplatin and vinorelbine. Combination regimens included are: cyclophosphamide+adriamycin+lomustine, cisplatin+vindesine, lomustine+cyclophosphamide+methotrexate+vindesine, cisplatin+etoposide; cisplatin+carboplatin and vinorelbine+cisplatin.
Participants included in the review
Patients with advanced NSCLC at stage IIIa, IIIb or stage IV of Mountain's (1986) classification were included.
Outcomes assessed in the review
Survival at one year was assessed.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.